Affordable Access

deepdyve-link
Publisher Website

Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population.

Authors
  • Bjermer, Leif1
  • van Boven, Job F M2, 3
  • Costa-Scharplatz, Madlaina4
  • Keininger, Dorothy L5
  • Gutzwiller, Florian S5
  • Lisspers, Karin6
  • Mahon, Ronan7
  • Olsson, Petter4
  • Roche, Nicolas8
  • 1 Department of Respiratory medicine & Allergology, Skane University Hospital, Lund University, Lund, Sweden. , (Sweden)
  • 2 Department of General Practice, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. , (Netherlands)
  • 3 Unit of Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands. , (Netherlands)
  • 4 Novartis Sverige AB, Täby, Sweden. , (Sweden)
  • 5 Novartis Pharma AG, Basel, Switzerland. , (Switzerland)
  • 6 Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden. , (Sweden)
  • 7 Novartis Ireland Limited, Dublin, Ireland. , (Ireland)
  • 8 Respiratory and Intensive Care Medicine, Cochin Hospital (AP-HP) and University Paris Descartes, Paris, France. [email protected] , (France)
Type
Published Article
Journal
Respiratory research
Publication Date
Dec 11, 2017
Volume
18
Issue
1
Pages
206–206
Identifiers
DOI: 10.1186/s12931-017-0688-5
PMID: 29228950
Source
Medline
Keywords
License
Unknown

Abstract

IND/GLY is a cost-effective treatment compared with SFC in COPD patients with mMRC dyspnea grade ≥ 2, moderate to very severe airflow limitation, and ≥1 exacerbation in the preceding year.

Report this publication

Statistics

Seen <100 times